ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 122 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2019 | $2,273,000 | -49.1% | 37,839 | -28.5% | 0.05% | -49.5% |
| Q2 2019 | $4,467,000 | +46.9% | 52,939 | +66.3% | 0.10% | +65.6% |
| Q1 2019 | $3,041,000 | +25.3% | 31,843 | -7.1% | 0.06% | +17.3% |
| Q4 2018 | $2,427,000 | +35.0% | 34,277 | +62.9% | 0.05% | +62.5% |
| Q3 2018 | $1,798,000 | -28.4% | 21,042 | -2.9% | 0.03% | -25.6% |
| Q2 2018 | $2,510,000 | +184.6% | 21,661 | +98.7% | 0.04% | +186.7% |
| Q1 2018 | $882,000 | -1.1% | 10,900 | -28.3% | 0.02% | 0.0% |
| Q4 2017 | $892,000 | +41.4% | 15,200 | +12.6% | 0.02% | 0.0% |
| Q3 2017 | $631,000 | +30.9% | 13,500 | +0.7% | 0.02% | +25.0% |
| Q2 2017 | $482,000 | +16.7% | 13,400 | 0.0% | 0.01% | +20.0% |
| Q1 2017 | $413,000 | -7.4% | 13,400 | +0.8% | 0.01% | -16.7% |
| Q4 2016 | $446,000 | – | 13,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 511,186 | $43,686,000 | 11.23% |
| GREAT POINT PARTNERS LLC | 210,400 | $17,981,000 | 2.80% |
| ARMISTICE CAPITAL, LLC | 456,000 | $38,970,000 | 2.34% |
| Matarin Capital Management, LLC | 210,208 | $17,964,376,000 | 1.16% |
| Sapphire Star Partners LP | 8,168 | $698,000 | 0.70% |
| Granahan Investment Management | 103,320 | $8,830,000 | 0.48% |
| FARALLON CAPITAL MANAGEMENT LLC | 867,500 | $74,137,000 | 0.44% |
| 361 CAPITAL LLC | 19,040 | $1,627,000 | 0.35% |
| ALGERT GLOBAL LLC | 17,922 | $1,532,000 | 0.33% |
| AlphaMark Advisors, LLC | 9,310 | $796,000 | 0.32% |